{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:33:41Z","timestamp":1790922821241,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1010882","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000}}],"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022111","name":"Huo Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W005611\/1"],"award-info":[{"award-number":["MR\/W005611\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Dormeur"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222433\/Z\/21\/Z"],"award-info":[{"award-number":["222433\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["208354\/Z\/17\/Z"],"award-info":[{"award-number":["208354\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N013700\/1"],"award-info":[{"award-number":["MR\/N013700\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/V509632\/1"],"award-info":[{"award-number":["BB\/V509632\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre at Guy's and St Thomas' Foundation Trust"},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2020EF-3008 COVAB"],"award-info":[{"award-number":["RIA2020EF-3008 COVAB"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022242","name":"Botnar Research Centre for Child Health, University of Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3\u20134 week) or extended interval (8\u201312 weeks) and following a third vaccination approximately 6\u20138 months later. We show that whilst an extended interval between the first two vaccinations can greatly increase the breadth of the immune response and generate a higher proportion of Spike reactive memory B cells, a third vaccination leads to similar levels between the two groups. Furthermore, we show that the third vaccine dose enhances neutralization activity against omicron lineage members BA.1, BA.2 and BA.4\/BA.5 and this is further increased following breakthrough infection during the UK omicron wave. These findings are relevant for vaccination strategies in populations where COVID-19 vaccine coverage remains low.<\/jats:p>","DOI":"10.1371\/journal.ppat.1010882","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T13:56:04Z","timestamp":1664805364000},"page":"e1010882","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern"],"prefix":"10.1371","volume":"18","author":[{"given":"Carl","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lechmere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-2342","authenticated-orcid":true,"given":"Ashwini","family":"Kurshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Huettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J. A.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry C. H.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Racz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anele","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Malim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-1725","authenticated-orcid":true,"given":"Katie J.","family":"Doores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"ppat.1010882.ref001","first-page":"e0379821","article-title":"Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals","volume":"2022","author":"T Lechmere","journal-title":"mBio"},{"key":"ppat.1010882.ref002","article-title":"Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3","author":"P Arora","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ppat.1010882.ref003","article-title":"Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies","author":"NA Doria-Rose"},{"issue":"3","key":"ppat.1010882.ref004","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","article-title":"mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant","volume":"28","author":"H Gruell","year":"2022","journal-title":"Nat Med"},{"key":"ppat.1010882.ref005","article-title":"Three-dose vaccination elicits neutralising antibodies against omicron","author":"M Wu","year":"2022","journal-title":"Lancet"},{"key":"ppat.1010882.ref006","unstructured":"Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination programme for maximum short-term impact. 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/prioritising-thefirst-covid-19-vaccine-dose-jcvi-statement\/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact. (cited 2022 July 6)"},{"issue":"24","key":"ppat.1010882.ref007","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning Immunity after the BNT162b2 Vaccine in Israel","volume":"385","author":"Y Goldberg","year":"2021","journal-title":"N Engl J Med"},{"key":"ppat.1010882.ref008","article-title":"Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine","author":"RR Goel","year":"2022","journal-title":"Cell"},{"issue":"19","key":"ppat.1010882.ref009","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar","volume":"386","author":"LJ Abu-Raddad","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"ppat.1010882.ref010","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"ppat.1010882.ref011","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1001\/jama.2022.0470","article-title":"Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants","volume":"327","author":"EK Accorsi","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"ppat.1010882.ref012","doi-asserted-by":"crossref","first-page":"e1008817","DOI":"10.1371\/journal.ppat.1008817","article-title":"Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings","volume":"16","author":"S Pickering","year":"2020","journal-title":"PLoS Pathog"},{"issue":"12","key":"ppat.1010882.ref013","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"J Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"58","key":"ppat.1010882.ref014","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"RR Goel","year":"2021","journal-title":"Sci Immunol"},{"issue":"10279","key":"ppat.1010882.ref015","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"C Manisty","year":"2021","journal-title":"Lancet"},{"key":"ppat.1010882.ref016","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","author":"L Stamatatos","year":"2021","journal-title":"Science"},{"key":"ppat.1010882.ref017","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","author":"CJ Reynolds","year":"2021","journal-title":"Science"},{"issue":"14","key":"ppat.1010882.ref018","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2","volume":"325","author":"S Saadat","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"ppat.1010882.ref019","doi-asserted-by":"crossref","first-page":"111276","DOI":"10.1016\/j.celrep.2022.111276","article-title":"A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination","volume":"40","author":"J Seow","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"ppat.1010882.ref020","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"183","author":"AC Walls","year":"2020","journal-title":"Cell"},{"issue":"6572","key":"ppat.1010882.ref021","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"RR Goel","year":"2021","journal-title":"Science"},{"issue":"637","key":"ppat.1010882.ref022","doi-asserted-by":"crossref","first-page":"eabn8057","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"JP Evans","year":"2022","journal-title":"Sci Transl Med."},{"issue":"6","key":"ppat.1010882.ref023","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.immuni.2020.10.023","article-title":"Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity","volume":"53","author":"H Liu","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"ppat.1010882.ref024","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/cbr.2009.0627","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"SI Rudnick","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"ppat.1010882.ref025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"A Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"8","key":"ppat.1010882.ref026","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.immuni.2021.07.015","article-title":"The unique biology of germinal center B cells","volume":"54","author":"C Young","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"ppat.1010882.ref027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/104063879901100106","article-title":"An IgG avidity ELISA to discriminate between recent and chronic Neospora caninum infection","volume":"11","author":"C Bjorkman","year":"1999","journal-title":"J Vet Diagn Invest"},{"key":"ppat.1010882.ref028","article-title":"Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5","author":"H Tegally","year":"2022","journal-title":"South Africa. Nat Med"},{"key":"ppat.1010882.ref029","unstructured":"UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 38. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file?1060337\/Technical-Briefing-38-11March2022.pdf. (cited 2022 July 6)"},{"issue":"23","key":"ppat.1010882.ref030","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"RP Payne","year":"2021","journal-title":"Cell"},{"issue":"1","key":"ppat.1010882.ref031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41541-022-00432-w","article-title":"Extended interval BNT162b2 vaccination enhances peak antibody generation.","volume":"7","author":"H Parry","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"1","key":"ppat.1010882.ref032","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1038\/s41467-022-30162-5","article-title":"Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants","volume":"13","author":"M Belik","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"ppat.1010882.ref033","doi-asserted-by":"crossref","first-page":"110429","DOI":"10.1016\/j.celrep.2022.110429","article-title":"SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"38","author":"D Chatterjee","year":"2022","journal-title":"Cell Rep"},{"key":"ppat.1010882.ref034","doi-asserted-by":"crossref","first-page":"110757","DOI":"10.1016\/j.celrep.2022.110757","article-title":"ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants","volume":"2022","author":"J Seow","year":"2022","journal-title":"Cell Rep"},{"issue":"7851","key":"ppat.1010882.ref035","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"C Gaebler","year":"2021","journal-title":"Nature"},{"issue":"8","key":"ppat.1010882.ref036","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"F Muecksch","year":"2021","journal-title":"Immunity"},{"issue":"7904","key":"ppat.1010882.ref037","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"W Kim","year":"2022","journal-title":"Nature"},{"issue":"7870","key":"ppat.1010882.ref038","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"JS Turner","year":"2021","journal-title":"Nature"},{"key":"ppat.1010882.ref039","article-title":"Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost","author":"F Muecksch","year":"2022","journal-title":"Nature"},{"issue":"16","key":"ppat.1010882.ref040","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMc2201849","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants","volume":"386","author":"J Yu","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1010882.ref041","article-title":"Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2","author":"JP Evans","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"1","key":"ppat.1010882.ref042","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJMc2206576","article-title":"Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5","volume":"387","author":"NP Hachmann","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1010882.ref043","article-title":"Neutralization of the SARS-CoV-2 Omicron BA.4\/5 and BA.2.12.1 Subvariants","author":"P Qu","year":"2022","journal-title":"N Engl J Med"},{"key":"ppat.1010882.ref044","article-title":"Distant antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5. bioRxiv","author":"BJ Willett"},{"key":"ppat.1010882.ref045","article-title":"Omicron infection enhances Delta antibody immunity in vaccinated persons","author":"K Khan","year":"2022","journal-title":"Nature"},{"key":"ppat.1010882.ref046","article-title":"Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection.","author":"CI Kaku","year":"2022","journal-title":"Sci Immunol"},{"key":"ppat.1010882.ref047","article-title":"SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals","author":"SI Richardson","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"9","key":"ppat.1010882.ref048","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.cell.2022.03.037","article-title":"Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice","volume":"185","author":"B Ying","year":"2022","journal-title":"Cell"},{"issue":"12","key":"ppat.1010882.ref049","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.cell.2022.05.014","article-title":"Potent cross-reactive antibodies following Omicron breakthrough in vaccinees","volume":"185","author":"R Nutalai","year":"2022","journal-title":"Cell"},{"key":"ppat.1010882.ref050","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","author":"A Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"ppat.1010882.ref051","doi-asserted-by":"crossref","first-page":"eabq1841","DOI":"10.1126\/science.abq1841","article-title":"Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure","author":"CJ Reynolds","year":"2022","journal-title":"Science"},{"key":"ppat.1010882.ref052","article-title":"Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada","author":"DM Skowronski","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"10277","key":"ppat.1010882.ref053","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"ppat.1010882.ref054","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.","volume":"22","author":"L Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"ppat.1010882.ref055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"H Parry","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11","key":"ppat.1010882.ref056","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"RT Shroff","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"ppat.1010882.ref057","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.ccell.2021.10.003","article-title":"Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer","volume":"39","author":"DR McKenzie","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"ppat.1010882.ref058","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"SK Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"ppat.1010882.ref059","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"SK Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"ppat.1010882.ref060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","article-title":"Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses","volume":"23","author":"VG Hall","year":"2022","journal-title":"Nat Immunol"},{"issue":"11","key":"ppat.1010882.ref061","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41564-021-00974-0","article-title":"Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern","volume":"6","author":"L Dupont","year":"2021","journal-title":"Nat Microbiol."},{"key":"ppat.1010882.ref062","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.mex.2015.09.003","article-title":"An optimised method for the production of MERS-CoV spike expressing viral pseudotypes","volume":"2","author":"K Grehan","year":"2015","journal-title":"MethodsX"},{"issue":"42","key":"ppat.1010882.ref063","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.42.2000685","article-title":"Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020","volume":"25","author":"CP Thompson","year":"2020","journal-title":"Euro Surveill"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1010882","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T14:11:46Z","timestamp":1665670306000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010882"}},"subtitle":[],"editor":[{"given":"Meike","family":"Dittmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":63,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010882","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.08.04.22278160","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}